Clinical Trial Update: A Study Using Rapid Acting Intramuscular Olanzapine in Agitated Patients With Schizophrenia [Phase 2]

View source ↗

Summary

Phase 2 study evaluating rapid-acting intramuscular olanzapine for agitation in patients with schizophrenia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• Zyprexa (olanzapine)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Schizophrenia | Phase 2 | Status: COMPLETED